Zogenix’ drug cuts seizures in Dravet syndrome
Zogenix has revealed top-line results from a second late-stage trial of its investigational Dravet syndrome drug ZX008, showing a significant reduction in seizures.
Read More
Tag: ZX008
- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
